drugset / Trial / NCT03153293

A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy

NCT03153293 ↗

NaSingle-groupOpen-labelTreatment

Summary

This study is meant to evaluate the safety and efficacy of rAAV2-ND4 treatment for Leber hereditary optic neuropathy with the G11778A mutation in mitochondrial DNA.

Timeline

Start
2017-12-27
Primary completion
2020-01-15
Completion
2025-01-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject rAAV2-ND4 Gene therapy (AAV / viral vector) 1e+10 vg Intravitreal